{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T03:16:26Z","timestamp":1761707786062},"reference-count":40,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2005,10,1]],"date-time":"2005-10-01T00:00:00Z","timestamp":1128124800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2005,10]]},"DOI":"10.1016\/j.leukres.2005.04.004","type":"journal-article","created":{"date-parts":[[2005,4,30]],"date-time":"2005-04-30T11:22:07Z","timestamp":1114860127000},"page":"1227-1232","source":"Crossref","is-referenced-by-count":11,"title":["Ph-Chromosome-positive chronic myeloid leukemia with associated bone marrow mastocytosis"],"prefix":"10.1016","volume":"29","author":[{"given":"Hermine","family":"Agis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karl","family":"Sotlar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Valent","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hans-Peter","family":"Horny","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.leukres.2005.04.004_bib1","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1111\/j.1365-2559.1979.tb03017.x","article-title":"Mast cells and mast cell neoplasia: a review","volume":"3","author":"Lennert","year":"1979","journal-title":"Histopathology"},{"key":"10.1016\/j.leukres.2005.04.004_bib2","doi-asserted-by":"crossref","first-page":"2S","DOI":"10.1111\/1523-1747.ep12468882","article-title":"Classification and diagnosis of mastocytosis: current status","volume":"96","author":"Metcalfe","year":"1991","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.leukres.2005.04.004_bib3","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1056\/NEJM199202273260912","article-title":"Systemic mastocytosis","volume":"326","author":"Austen","year":"1992","journal-title":"N Engl J Med"},{"key":"10.1016\/j.leukres.2005.04.004_bib4","first-page":"385","article-title":"Biology, classification and treatment of human mastocytosis","volume":"108","author":"Valent","year":"1996","journal-title":"Wien Klin Wschr"},{"key":"10.1016\/j.leukres.2005.04.004_bib5","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/S0145-2126(01)00038-8","article-title":"Diagnostic criteria and classification of mastocytosis: a consensus proposal","volume":"25","author":"Valent","year":"2001","journal-title":"Leuk Res"},{"key":"10.1016\/j.leukres.2005.04.004_bib6","first-page":"291","article-title":"World health organization (WHO) classification of tumours pathology and genetics","volume":"vol. 1","author":"Valent","year":"2001"},{"key":"10.1016\/j.leukres.2005.04.004_bib7","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1016\/S0889-8588(03)00089-3","article-title":"Mast cell proliferative disorders: current view on variants recognized by the World Health Organization","volume":"17","author":"Valent","year":"2003","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1016\/j.leukres.2005.04.004_bib8","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1097\/00000478-199809000-00013","article-title":"Diagnostic utility of staining for tryptase in patients with mastocytosis","volume":"22","author":"Horny","year":"1998","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.leukres.2005.04.004_bib9","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/S0145-2126(01)00021-2","article-title":"Diagnosis of mastocytosis: general histopathological aspects, morphological criteria, and immunohistochemical findings","volume":"25","author":"Horny","year":"2001","journal-title":"Leuk Res"},{"key":"10.1016\/j.leukres.2005.04.004_bib10","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1159\/000048180","article-title":"Histopathological and immunohistochemical aspects of mastocytosis","volume":"127","author":"Horny","year":"2002","journal-title":"Int Arch Allergy Immunol"},{"key":"10.1016\/j.leukres.2005.04.004_bib11","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1002\/1097-0142(19880901)62:5<965::AID-CNCR2820620520>3.0.CO;2-M","article-title":"Significance of systemic mast cell disease with associated hematologic disorders","volume":"62","author":"Travis","year":"1988","journal-title":"Cancer"},{"key":"10.1016\/j.leukres.2005.04.004_bib12","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1111\/j.1365-2141.1990.tb07870.x","article-title":"Blood findings in generalized mastocytosis: evidence of frequent simultaneous occurrence of myeloproliferative disorders","volume":"76","author":"Horny","year":"1990","journal-title":"Br J Haematol"},{"key":"10.1016\/j.leukres.2005.04.004_bib13","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/0002-9343(91)90214-I","article-title":"Hematologic manifestation of systemic mast cell disease: a prospective study of laboratory and morphologic features and their relation to prognosis","volume":"91","author":"Lawrence","year":"1991","journal-title":"Am J Med"},{"key":"10.1016\/j.leukres.2005.04.004_bib14","doi-asserted-by":"crossref","first-page":"3093","DOI":"10.1182\/blood-2003-05-1627","article-title":"CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy","volume":"102","author":"Pardanani","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2005.04.004_bib15","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1532\/IJH97.04046","article-title":"Imatinib therapy in clonal eosinophilic disorders, including systemic mastocytosis","volume":"79","author":"Tefferi","year":"2004","journal-title":"Int J Hematol"},{"key":"10.1016\/j.leukres.2005.04.004_bib16","first-page":"871","article-title":"FIP1L1-PDGFRA and c-kit D816V mutation-based clonality studies in systemic mast cell disease associated with eosinophilia","volume":"89","author":"Tefferi","year":"2004","journal-title":"Haematologica"},{"key":"10.1016\/j.leukres.2005.04.004_bib17","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/S0002-9440(10)63870-9","article-title":"One-step detection of c-kit point mutations using peptide nucleic acid-mediated polymerase chain reaction clamping and hybridization probes","volume":"162","author":"Sotlar","year":"2003","journal-title":"Am J Pathol"},{"key":"10.1016\/j.leukres.2005.04.004_bib18","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1016\/S0145-2126(02)00041-3","article-title":"Detection of c-kit point mutation Asp-816 \u2192 Val in microdissected pooled single mast cells and leukemic cells in a patient with systemic mastocytosis and concomitant chronic myelomonocytic leukemia","volume":"26","author":"Sotlar","year":"2002","journal-title":"Leuk Res"},{"key":"10.1016\/j.leukres.2005.04.004_bib19","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1159\/000059404","article-title":"Serum tryptase levels in patients with mastocytosis: correlation with mast cell burden and implication for defining the category of disease","volume":"128","author":"Sperr","year":"2002","journal-title":"Int Arch Allergy Immunol"},{"key":"10.1016\/j.leukres.2005.04.004_bib20","doi-asserted-by":"crossref","first-page":"473","DOI":"10.3109\/10428190009058500","article-title":"Clinical and biologic diversity of leukemias occurring in patients with mastocytosis","volume":"37","author":"Sperr","year":"2000","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.leukres.2005.04.004_bib21","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1159\/000048186","article-title":"Spectrum of associated clonal hematologic non-mast cell lineage disorders occurring in patients with systemic mastocytosis","volume":"127","author":"Sperr","year":"2002","journal-title":"Int Arch Allergy Immunol"},{"key":"10.1016\/j.leukres.2005.04.004_bib22","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1136\/jcp.2003.014860","article-title":"Systemic mastocytosis with associated clonal haematological non-mast cell lineage diseases: a histopathological challenge","volume":"57","author":"Horny","year":"2004","journal-title":"J Clin Pathol"},{"key":"10.1016\/j.leukres.2005.04.004_bib23","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1136\/jcp.2003.012864","article-title":"Acute myeloid leukaemia with t(8;21) associated with occult mastocytosis. Report of an unusual case and review of the literature","volume":"57","author":"Bernd","year":"2004","journal-title":"J Clin Pathol"},{"key":"10.1016\/j.leukres.2005.04.004_bib24","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1097\/01.pas.0000138181.89743.7b","article-title":"CD25 Indicates the neoplastic phenotype of mast cells: a novel immunohistochemical marker for the diagnosis of systemic mastocytosis (sm) in routinely processed bone marrow biopsy specimens","volume":"28","author":"Sotlar","year":"2004","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.leukres.2005.04.004_bib25","doi-asserted-by":"crossref","first-page":"2731","DOI":"10.1182\/blood.V91.8.2731.2731_2731_2736","article-title":"Indolent systemic mast cell disease in adults: immunophenotypic characterization of bone marrow mast cells and its diagnostic implication","volume":"91","author":"Escribano","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2005.04.004_bib26","doi-asserted-by":"crossref","first-page":"10560","DOI":"10.1073\/pnas.92.23.10560","article-title":"Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder","volume":"92","author":"Nagata","year":"1995","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.leukres.2005.04.004_bib27","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1038\/ng0396-312","article-title":"Somatic c-kit activating mutation in urticaria pigmentosa and aggressive mastocytosis: establishment of clonality in a human mast cell neoplasm","volume":"12","author":"Longley","year":"1996","journal-title":"Nature Genet"},{"key":"10.1016\/j.leukres.2005.04.004_bib28","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1046\/j.1365-2141.2001.02783.x","article-title":"Mutation analysis of c-kit in patients with myelodysplastic syndromes without mastocytosis and cases of systemic mastocytosis","volume":"113","author":"Fritsche-Polanz","year":"2001","journal-title":"Br J Haematol"},{"key":"10.1016\/j.leukres.2005.04.004_bib29","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/S0301-472X(99)00145-9","article-title":"Analysis of the surface expression of c-kit and occurrence of the c-kit Asp816Val activating mutation in T cells, B cells, and myelomonocytic cells in patients with mastocytosis","volume":"28","author":"Akin","year":"2000","journal-title":"Exp Hematol"},{"key":"10.1016\/j.leukres.2005.04.004_bib30","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1046\/j.1365-2141.1998.01072.x","article-title":"Systemic mastocytosis associated with acute myeloid leukaemia: report of two cases and detection of the c-kit mutation Asp-816 to Val","volume":"103","author":"Sperr","year":"1998","journal-title":"Br J Haematol"},{"key":"10.1016\/j.leukres.2005.04.004_bib31","doi-asserted-by":"crossref","first-page":"2702","DOI":"10.1172\/JCI118337","article-title":"The alpha form of human tryptase is the predominant type present in blood at baseline in normal subjects and is elevated in those with systemic mastocytosis","volume":"96","author":"Schwartz","year":"1995","journal-title":"J Clin Invest"},{"key":"10.1016\/j.leukres.2005.04.004_bib32","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1056\/NEJM198706253162603","article-title":"Tryptase levels as an indicator of mast-cell activation in systemic anaphylaxis and mastocytosis","volume":"316","author":"Schwartz","year":"1987","journal-title":"N Engl J Med"},{"key":"10.1016\/j.leukres.2005.04.004_bib33","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1159\/000059404","article-title":"Serum tryptase levels in patients with mastocytosis: correlation with mast cell burden and implication for defining the category of disease","volume":"128","author":"Sperr","year":"2002","journal-title":"Int Arch Allergy Immunol"},{"key":"10.1016\/j.leukres.2005.04.004_bib34","doi-asserted-by":"crossref","first-page":"2200","DOI":"10.1182\/blood.V98.7.2200","article-title":"Expression of mast cell tryptase by myeloblasts in a group of patients with acute myeloid leukemia","volume":"98","author":"Sperr","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2005.04.004_bib35","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1080\/10428190290021470","article-title":"Serum tryptase measurements in patients with myelodysplastic syndromes","volume":"43","author":"Sperr","year":"2002","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.leukres.2005.04.004_bib36","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/S0301-472X(03)00112-7","article-title":"Effects of tyrosine kinase inhibitor STI571 on human mast cells bearing wild-type or mutated forms of c-kit","volume":"31","author":"Akin","year":"2003","journal-title":"Exp Hematol"},{"key":"10.1016\/j.leukres.2005.04.004_bib37","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1182\/blood.V99.5.1741","article-title":"The c-kit mutation causing human mastocytosis is resistant to STI571 and other KIT kinase inhibitors; kinases with enzymatic site mutations show different inhibitor sensitivity profiles than wild-type kinases and those with regulatory type mutations","volume":"99","author":"Ma","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2005.04.004_bib38","first-page":"1115","article-title":"Juxtamembrane mutant V560GKit is more sensitive to Imatinib (STI571) compared with wild-type c-kit whereas the kinase domain mutant D816VKit is resistant","volume":"1","author":"Frost","year":"2002","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.leukres.2005.04.004_bib39","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1111\/j.0960-135X.2004.01369.x","article-title":"On the way to targeted therapy of mast cell neoplasms: identification of molecular targets in neoplastic mast cells and evaluation of arising treatment concepts","volume":"34","author":"Valent","year":"2004","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.leukres.2005.04.004_bib40","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.leukres.2003.09.004","article-title":"Treatment of systemic mast cell disease: beyond interferon","volume":"28","author":"Tefferi","year":"2004","journal-title":"Leuk Res"}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212605001669?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212605001669?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,4,7]],"date-time":"2020-04-07T05:00:40Z","timestamp":1586235640000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212605001669"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,10]]},"references-count":40,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2005,10]]}},"alternative-id":["S0145212605001669"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2005.04.004","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2005,10]]}}}